Pregabalin in clinical psychiatry. Frequently asked questions and doubts Review article
Article Sidebar
Published:
Jun 30, 2018
Keywords:
pregabalin, anxiety disorders, pain, treatment
Main Article Content
Abstract
General practitioner have to quickly control the anxiety symptoms in order to quickly implement long-term therapy. The drug that allows this and at the same time relieves possible pain is pregabalin. This drug works best in generalized anxiety. Due to the low risk of interaction, it can be used in patients who require anxiolytics and already take neuroleptics or mood stabilizers. It can also be used in patients addicted to benzodiazepines.
Article Details
How to Cite
Tafliński, T. (2018). Pregabalin in clinical psychiatry. Frequently asked questions and doubts. Medycyna Faktow (J EBM), 11(2(39), 118-124. https://doi.org/10.24292/01.MF.0218.3
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Baxter A.J., Scott K.M., Vos T., Whiteford H.A.: Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol. Med. 2013; 43(5): 897-910.
2. Lydiard R.B., Rickels K., Herman B., Feltner D.E.: Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 2010; 13(2): 229-241.
3. Cross A.L., Sherman A.: Pregabalin. W: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2018. 2017 Dec 5.
4. Sałat K., Gdula-Argasińska J., Malikowska N. et al.: Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice. Naunyn-Schmiedeberg’s Archives of Pharmacology 2016; 389: 613-623.
5. Charakterystyki produktów leczniczych pregabaliny dostępne obecnie na rynku polskim (źródło: Internet).
6. Arnold L., Choy E., Clauw D.J. et al.: An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr. Med. Res. Opin. 2018: 1-26.
7. Baandrup L., Ebdrup B.H., Rasmussen J.Ø. et al.: Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst. Rev. 2018; 3: CD011481.
8. Zellner N., Eyer F., Zellner T.: Alarming Pregabalin Abuse in Munich: Prevalence, Patterns of Use and Complications. Dtsch. Med. Wochenschr. 2017; 142(19): e140-e147.
9. Gimeno C., Dorado M.L., Roncero C. et al.: Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment. Front. Psychiatry. 2017; 8: 173.
2. Lydiard R.B., Rickels K., Herman B., Feltner D.E.: Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 2010; 13(2): 229-241.
3. Cross A.L., Sherman A.: Pregabalin. W: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2018. 2017 Dec 5.
4. Sałat K., Gdula-Argasińska J., Malikowska N. et al.: Effect of pregabalin on contextual memory deficits and inflammatory state-related protein expression in streptozotocin-induced diabetic mice. Naunyn-Schmiedeberg’s Archives of Pharmacology 2016; 389: 613-623.
5. Charakterystyki produktów leczniczych pregabaliny dostępne obecnie na rynku polskim (źródło: Internet).
6. Arnold L., Choy E., Clauw D.J. et al.: An evidence-based review of pregabalin for the treatment of fibromyalgia. Curr. Med. Res. Opin. 2018: 1-26.
7. Baandrup L., Ebdrup B.H., Rasmussen J.Ø. et al.: Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst. Rev. 2018; 3: CD011481.
8. Zellner N., Eyer F., Zellner T.: Alarming Pregabalin Abuse in Munich: Prevalence, Patterns of Use and Complications. Dtsch. Med. Wochenschr. 2017; 142(19): e140-e147.
9. Gimeno C., Dorado M.L., Roncero C. et al.: Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment. Front. Psychiatry. 2017; 8: 173.